Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib versus teriflunomide in relapsing multiple sclerosis
NL-OMON54410Phase 3Recruiting
- Sponsor
- Roche
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenebrutinib in multiple sclerosis (MS) (2 arms), sponsored by Roche. Primary endpoint: Annualized relapse rate. Started Oct 2022; status: recruiting.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON54410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54410.